The Binding Site’s Post

In this article featured in AJMC - The American Journal of Managed Care, presenters from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition discuss outcome disparities and the burden of multiple myeloma, which remains substantially higher among Black patients than White patients. Learn more!

Especially lessons about clinical suspicion and complete blood cell abnormalities should be taught #bloodcancerawereness

NEW #Thalassemia Sessions from #ASH23🩸 💬 In this session, leading experts Maria Domenica Cappellini & Kevin Kuo discuss exciting updates in #thalassemia presented at the 2023 ASH Annual Meeting and Exposition The experts cover several topics, including the promise of novel #genetherapies, ongoing #clinicaltrials in the field, and the value of #precisionmedicine 🔬 Take a look 👉 https://lnkd.in/e2-JsM7Y #HemOnc #MPNsm American Society of Hematology

Hematology focuses on treating disorders of the blood and is a large part of our practice and the patients we treat at FCS. Over the past several days, scientific abstracts from early and late-phase research submitted by FCS hematologists and medical oncologists have been presented at the American Society of Hematology 65th Annual Meeting and Exposition. Among the numerous studies featuring research conducted by FCS physicians, FCS president and managing physician Lucio N. Gordan, MD was first author of a comparative study of first-line treatment for patients newly diagnosed with multiple myeloma. Read about these breaking discoveries: https://lnkd.in/e-8cK3t3

Last week I presented the first results of the phase 2 ICON study at the European Hematology Association (EHA) conference in Madrid. In the ICON study, relapsed/refractory multiple myeloma patients were treated with iberdomide, low-dose cyclophosphamide and dexamethasone. Iberdomide is a novel cereblon E3 ligase modulator (CELMoD™) with improved direct anti-myeloma activity and immune-stimulatory effects. This treatment regimen resulted in a ORR of 82% and a median PFS of 17.8 months in patients with 2-4 prior lines of therapy. This fully oral, well tolerated, and active combination warrants further evaluation in RRMM. The full abstract is available online: https://lnkd.in/eUqb4Vaq What an interesting conference the #EHA2024 has been! Thanks to all co-authors and my supervisors Niels Van De Donk, Sonja Zweegman and Tuna Mutis.

NEW #MPN Session from #ASH23🩸 💬 This EXCLUSIVE discussion features leading experts Ruben Mesa, MD, Claire Harrison & Jean-Jacques Kiladjian, who discuss key updates in the #treatment and #management of #myeloproliferativeneoplasms (#MPNs) following the 65th ASH Annual Meeting and Exposition The experts cover a variety of topics, including #novelagents being explored in essential #thrombocythemia (ET), updates in the treatment of #polycythemiavera (PV), and novel combinations being evaluated in #myelofibrosis (MF) 🔦 Take a look 👉 https://lnkd.in/eXeXjSFj #HemOnc #MPNsm American Society of Hematology

🙋🏻♂️ The European Hematology Association (EHA) Congress started today. It is interesting to see the number of sessions dedicated to patient centricity. Patient perspective is essential for understanding their experience along the disease journey. #EHA2024 #patientcentricity #patientadvocacy

We are excited to provide updated clinical safety and efficacy data from 7 transfusion-dependent beta thalassemia patients treated with renizgamglogene autogedtemcel (reni-cel) in the Phase 1/2 EdiThal clinical trial at European Hematology Association (EHA) annual congress. Treated patients had early and robust increases of total hemoglobin (Hb) and fetal hemoglobin, with total Hb rising to or above the transfusion independence threshold of 9.0 g/dL. All patients have been transfusion free for a range of 4.1 to 12.8 months after receiving the last red blood cell transfusion at 0.5–2.2 months post-reni-cel infusion. Reni-cel was well-tolerated and continues to demonstrate a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant. #BetaThalassemia #Biotechnology #Cas12a #CellTherapy #ClinicalTrials #CRISPR #EHA #GeneEditing #Hematology

Do carve out time in your busy schedule to meet Jennell and learn about RBC health biomarkers.

Higher-risk #Myelofibrosis: Learn more about the selection and initiation of 2nd-line therapies for patients: New #CME #CE available on the Hematology Advisor Institute, powered by myCME. https://brnw.ch/21wGTM9